Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 1998 June;40(2) > Panminerva Medica 1998 June;40(2):110-5

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

ORIGINAL ARTICLES  


Panminerva Medica 1998 June;40(2):110-5

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

Clinical efficacy and tolerance of nabumetone in articular and non-articular rheumatic disorders: personal experience during 12 weeks of treatment

Coaccioli S., Allegra A., Di Cato L., Puxeddu A.

From the Department of Internal Medicine and Rheumatology Medicine “S. Maria” Hospital, Terni, Italy


PDF  


Background. We eval­u­at­ed the clin­i­cal effi­ca­cy and the tol­er­ance of Nabumetone (N), in com­par­i­son ­with a ­pool of non-ster­oid­al ­anti-inflam­ma­to­ry ­drugs (NSAIDs), in a ­cohort of ­patients affect­ed by rheu­ma­toid ­arthritis, oste­oar­thritis, non-artic­u­lar rheu­ma­tisms and pri­mary fibro­myal­gic syn­drome.
Methods. One hun­dred and sev­en­ty ­patients ­were ­observed in an ­open-non ran­dom­ized ­study. The ­patients ­have ­been recruited alter­na­tive­ly and sub­di­vid­ed into two ­groups: 84 ­patients ­that ­received N and 86 ­patients ­that ­received one of the oth­er NSAIDs. All the ­patients affect­ed by rheu­ma­toid ­arthritis ­received a dis­ease-mod­i­fy­ing ­anti-rheu­mat­ic ­drug (OH-chlor­o­quine, d-pen­i­cil­la­mine, auran­o­fin, cyclo­spo­rine-A); ­while ben­zod­i­az­e­pines are admin­is­tered in the ­patients suf­fer­ing ­from pri­mary fibro­myal­gic syn­drome. A fol­low-up not infe­ri­or to 12 con­sec­u­tive ­weeks was real­ized and the fol­low­ing clin­i­cal param­e­ters ­were stud­ied: spon­ta­ne­ous ­pain, pro­voked ­pain, ­pain on ­active move­ment, ­pain on pas­sive move­ment, ­pain at ris­ing, ­pain at bed ­time, morn­ing stiff­ness, lim­it­ed ­joint mobil­ity, num­ber of ten­der ­points, num­ber of affect­ed ­joints and num­ber of swol­len ­joints. All the ­patients ­were moni­tor­ed for hemat­o­log­i­cal, bio­chem­i­cal, uri­nary and clot­ting ­tests.
Results. The ­results ­revealed an excel­lent tol­er­abil­ity of nabu­me­tone ­with a clin­i­cal effi­ca­cy not infe­ri­or to the NSAIDs’ ­pool. Moreover, the num­ber of ­drop-outs in the N-­group ­were sig­nif­i­cant­ly infe­ri­or in com­par­i­son to the NSAIDs’-­pool ­group.
Conclusions. We con­clude ­that N can be con­sid­ered as effec­tive as oth­er NSAIDs. Moreover it ­seems to be bet­ter tol­er­at­ed ­that the oth­er NSAIDs util­i­zed in our ­study.

top of page

Publication History

Cite this article as

Corresponding author e-mail